Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

People diagnosed with type 2 diabetes before age 40 face a higher lifetime risk of heart and kidney problems, so may benefit from adding another type of medicine called a GLP-1 receptor agonist (such ...

Lantidra therapy infuses healthy islet cells into patients' livers, with some achieving insulin independence. University ...

Weight loss medications Mounjaro and Zepbound, which contain the active ingredient tirzepatide, may lower the risk of ...

Treating kidney disease GLP-1s show higher risk than SGLT2 inhibitors in kidney outcomes, but lower albuminuria and mortality rates.

Diabetes is the most common cause of chronic kidney disease (CKD). Around 33 percent of adults with diabetes also have CKD. When diabetes causes CKD, its sometimes called diabetic kidney disease.

Living with diabetes doesn’t have to mean accepting a lifetime of increasing medication doses and constant worry about blood sugar spikes. While traditional medical approaches focus heavily on ...

The landscape of diabetes management is undergoing a remarkable transformation. Groundbreaking research has uncovered surprising cardiovascular benefits tied to modern medications, offering new hope ...

In the United States, over 30 million people suffer from diabetes, while nearly 98 million are classified as pre-diabetic. Unfortunately, rather than addressing the fundamental lifestyle factors that ...

A study led by the Joslin Diabetes Center found that bariatric metabolic surgery is more effective at glycemic and weight ...